MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 228 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,342 | -36.8% | 77,657 | 0.0% | 8.78% | -33.1% |
| Q2 2023 | $17,939 | -4.7% | 77,657 | 0.0% | 13.14% | -12.2% |
| Q1 2023 | $18,814 | -16.5% | 77,657 | 0.0% | 14.97% | -11.7% |
| Q4 2022 | $22,540 | -99.6% | 77,657 | 0.0% | 16.95% | +412.3% |
| Q3 2022 | $5,047,000 | -9.2% | 77,657 | 0.0% | 3.31% | -14.0% |
| Q2 2022 | $5,559,000 | -27.0% | 77,657 | 0.0% | 3.85% | +38.5% |
| Q1 2022 | $7,620,000 | +15.8% | 77,657 | 0.0% | 2.78% | +38.2% |
| Q4 2021 | $6,581,000 | +60.5% | 77,657 | +51.1% | 2.01% | +84.0% |
| Q3 2021 | $4,101,000 | -18.1% | 51,396 | 0.0% | 1.09% | -4.9% |
| Q2 2021 | $5,007,000 | -16.7% | 51,396 | 0.0% | 1.15% | -33.8% |
| Q1 2021 | $6,012,000 | +5.2% | 51,396 | 0.0% | 1.74% | +23.6% |
| Q4 2020 | $5,714,000 | -6.4% | 51,396 | 0.0% | 1.40% | -28.6% |
| Q3 2020 | $6,103,000 | – | 51,396 | – | 1.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |